Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bf-688 in ADHD
NCT04958460Phase 3Completed
- Start
- May 2020
- Primary completion
- Feb 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of bifidobacterium bifidum in attention deficit hyperactivity disorder (ADHD). Started May 2020; status: completed.
02
Drugs
bifidobacterium bifidum
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04958460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958460.